Bruce McCreedy, PhD

Chief Science Officer

Dr. McCreedy has over 30 years of experience in the development and approval of drugs for the treatment of infectious diseases, autoimmune disorders, and cancer. Prior to joining Myeloid Therapeutics Dr. McCreedy served as Senior Vice President Cell Therapy and Immuno-Oncology Research at Precision BioSciences, Inc. where he oversaw the development of a portfolio of gene edited allogeneic CAR T therapies. Previous industry positions held by Dr. McCreedy include Executive Vice President and Chief Development Officer for Neximmune, Inc., President and CEO of Fulcrum Pharma Developments, Inc. and Vice President of Clinical Virology and Diagnostics for Triangle Pharmaceuticals, Inc. (now Gilead Sciences). Dr. McCreedy obtained a BS in medical microbiology from Wake Forest University and a PhD in microbiology and immunology from the Wake Forest University School of Medicine

Daniel Getts_web_Silhouette_reallo copy.